[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369217-105":59,"doc-detail-369217-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","understanding-diagnostic-costs-using-hospital-based-encounters-in-the-year-before-diagnosis-for-canadian-patients-with-malignant-central-nervous-system-tumours-compared-to-common-cancers","Understanding Diagnostic Costs Using Hospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers","","Rare cancers pose significant diagnostic challenges, leading to more tests and higher healthcare expenditures (HEs). Understanding the financial implications of diagnosing rare cancers is crucial, particularly in Canada, where overall HEs are high. The study examined pre-diagnostic hospital-based HEs for patients with malignant central nervous system (CNS) tumours and compared them with patients with common cancers across Canadian provinces using in-patient and ambulatory data from 2010–2014, applying quantile regression and adjusted effects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-diagnostic-costs-using-hospital-based-encounters-in-the-year-before-diagnosis-for-canadian-patients-with-malignant-central-nervous-system-tumours-compared-to-common-cancers/369217/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-diagnostic-costs-using-hospital-based-encounters-in-the-year-before-diagnosis-for-canadian-patients-with-malignant-central-nervous-system-tumours-compared-to-common-cancers/369217.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were pre-diagnostic healthcare expenditures (HEs) calculated for CNS tumour patients?","Question",{"text":112,"@type":113},"Pre-diagnostic HE was computed as the change in total HE during the 12 months before diagnosis, defined as the HE in that period minus the estimated average annual HE from the two preceding years.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which comparison cancers and patient groups were used in the analysis?",{"text":117,"@type":113},"The study compared malignant CNS tumour patients with pediatric patients diagnosed with leukemia, and with patients aged over 15 diagnosed with colorectal cancer and lung cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main factors associated with variation in pre-diagnostic costs?",{"text":121,"@type":113},"The top three contributors were encounter type (in-patient vs. out-patient), province (Alberta vs. Ontario), and comorbidities (yes/no).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369217,1790459299,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nUnderstanding Diagnostic Costs Using Hospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers  \nLinwan Xu 1, Keyun Zhou 1, Yan Yuan 1 and Emily V. Walker 1,2, *  \nReceived: 29 November 2024  \nRevised: 1 February 2025  \nAccepted: 7 February 2025  \nPublished: 9 February 2025  \nCitation: Xu, L.; Zhou, K.; Yuan, Y.; Walker, E.V. Understanding Diagnostic Costs Using  \nHospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers. Curr. Oncol. 2025, 32, 96. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/curroncol32020096](10.3390/curroncol32020096)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 School of Public Health, University of Alberta, Edmonton, AB T6G 1C9, Canada; [linwan2@ualberta.ca](linwan2@ualberta.ca) (L.X.); [keyun1@ualberta.ca](keyun1@ualberta.ca) (K.Z.); [yyuan@ualberta.ca](yyuan@ualberta.ca) (Y.Y.)  \n2 Precision Analytics, Cancer Research & Analytics, Cancer Care Alberta, Alberta Health Services, Edmonton, AB T5J 3C6, Canada  \n* Correspondence: [emily.walker@albertahealthservices.ca](emily.walker@albertahealthservices.ca)  \nAbstract: Rare cancers pose significant diagnostic challenges, leading to more tests and higher healthcare expenditures (HEs) . Understanding the financial implications of diagnosing rare cancers is crucial, particularly in Canada, where overall HEs are high (12% of the GDP in 2023) . We investigated the pre-diagnostic hospital–based HE for patients with malignant central nervous system (CNS) tumours and compared it to patients with common cancers across Canadian provinces, using in-patient and ambulatory care data (2010–2014) from the Canadian Institute for Health Information. Pre-diagnostic HE was calculated as the change in total HE (in-patient and out-patient) during the 12 months before diagnosis, calculated as the HE within this period minus the average annual HE estimated over the two preceding years. Comparison groups included pediatric patients diagnosed with leukemia and patients aged over 15 diagnosed with colorectal cancer and lung cancer. We used quantile regression to estimate the adjusted effect of diagnosis with a CNS tumour on pre-diagnostic HE. The results indicated that HE for CNS patients was higher compared to those with common cancers. The top three factors contributing to HE variation were encounter type (in-patient/out-patient), province (Alberta/Ontario), and comorbidities (yes/no) . Further investigation is warranted to understand the drivers of the cost differences.  \nKeywords: Canada; central nervous system cancer; colorectal cancer; diagnostic cost analysis; leukemia; lung cancer; quantile regression  \n1. Introduction  \nThere is no universal definition for rare cancer [1,2] . In the European Union, a rare cancer is defined as one that affects fewer than 6 people per 100,000 annually [1] . In the United States, the threshold is fewer than 15 cases per 100,000 people annually [2] . While individually rare, these cancers collectively account for a substantial portion of all cancer diagnoses. Walker et al. [3] estimated that in Canada, 17.0% and 34.4% of annual cancer diagnoses were rare based on EU and U.S. definitions, respectively. Diagnosing rare cancers can pose a challenge due to their low incidence, which may lead to limited clinical experience in primary care settings. Additionally, the constellation of symptoms in the early stages may be non-specific and resemble those of more common conditions, which may contribute to misdiagnosis or delays in diagnosis [4] . Timely ","cbCaiipFflg9RPJ4","https://ap.wps.com/l/cbCaiipFflg9RPJ4","pdf",3750218,13,"English","# Introduction\n## Methods\n### Data Coverage and Datasets","[{\"question\":\"How were pre-diagnostic healthcare expenditures (HEs) calculated for CNS tumour patients?\",\"answer\":\"Pre-diagnostic HE was computed as the change in total HE during the 12 months before diagnosis, defined as the HE in that period minus the estimated average annual HE from the two preceding years.\"},{\"question\":\"Which comparison cancers and patient groups were used in the analysis?\",\"answer\":\"The study compared malignant CNS tumour patients with pediatric patients diagnosed with leukemia, and with patients aged over 15 diagnosed with colorectal cancer and lung cancer.\"},{\"question\":\"What were the main factors associated with variation in pre-diagnostic costs?\",\"answer\":\"The top three contributors were encounter type (in-patient vs. out-patient), province (Alberta vs. Ontario), and comorbidities (yes/no).\"}]","Understanding Diagnostic Costs Using Hospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers | PDF",1790181439,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93e027aef509cff47343d838932520a2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/175c843cc12d632f93f02ff0633d9fe4.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/689e32f6a753c5a8240cf056f846e1d5.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5928b383876a408f28e0600afe1a2063.webp",980,1385]